To help pharmaceutical brands deliver faster-to-market nasal spray solutions, Silgan Dispensing, a global leader in the design, development and distribution of highly engineered pumps and sprayers in the pharmaceutical, home and beauty markets, announces the launch of the Gemini™ BE Nasal Pump.
Developed with Silgan Dispensing’s Bioequivalence (BE) Program, the Gemini™ BE Nasal Pump is adaptable to effectively match specific formulations for a perfect performance fit and quick time-to-market. With an extensive five-stage custom process, Gemini™ allows for ultimate customizability with over 40 different spray configurations.
Additional benefits of the Gemini™ BE Nasal Pump include:
· Cleanroom, pharma-grade, and ISO-certified production
· High-dosing accuracy
· Low strokes to prime
· Capability to match existing reference listed drug (RLD) devices across a range of formulations
· Ability to modify spray characteristics like DSD, plume geometry, and spray pattern
“Bioequivalence testing helps our customers overcome regulatory and technical barriers that have previously slowed product commercialization,” said Allan Houston, vice president sales & marketing, healthcare at Silgan Dispensing. “The Gemini™ BE Nasal Pump showcases our BE Program and Silgan Dispensing’s ability to deliver expedited nasal devices that fit our customers’ needs as a replacement or secondary supply chain option.”
Silgan Dispensing’s BE Program is aligned with U.S. FDA and EU methods – providing customers the confidence they require from a healthcare packaging supplier. Additionally, the BE Program is supported by Silgan Dispensing’s regulatory team, utilizing the company’s Nasal Spray Testing cGMP lab and equipment, and partners with accredited, external cGMP lab testing services and CMOs for nasal products.
Attendees and media are invited to get a firsthand look at the Gemini™ BE Nasal pump at Booth 30A80 in Hall 3.0.
